



ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results

July 18, 2019

WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 18, 2019-- [ImmunoGen, Inc.](#), (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 2, 2019 to discuss its second quarter operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, dial +1-323-794-2093; the conference ID is 9100112. The call may also be accessed through the Investors section of the Company's website, www.immunogen.com. Following the webcast, a replay of the call will be available at the same location through August 16, 2019.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now." The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190718005731/en/>

Source: ImmunoGen, Inc.

INVESTOR RELATIONS AND MEDIA

Courtney O'Konek
781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657

robert.stanislaro@fticonsulting.com